… licensed a set of patents that originated with Roche. … s exclusive use of the patents. Sandoz’ former owner, Novartis … have Amgen’s Enbrel patents invalidated, but lost in … which was originally developed by BioMarin Pharmaceutical and then Allievex, …

… infringe BioMarin's patent. The BioMarin patent was confirmed by the European Patent Office … of one of BioMarin's European patents, including BioMarin's expectations … the Unified Patent Court; and those factors detailed in BioMarin's …

Patent owner has chosen the EU court for the opening move in what promises to be a fierce battle with rival Ascendis Pharma Register for limited access Register to receive our newsletter and gain limited access to subscriber content. Register now Subscribe …

… Read: Rare Disease-Focused BioMarin Narrows Sales Focus, Cuts … type natriuretic peptide (CNP) patents. However, excluding this concern … upside and diversification beyond BioMarin's guidance. … increasing competitive pressure on BioMarin's key …

… AGV) superior to placebo. BioMarin Pharmaceutical Inc’s BMRN stock … TransCon CNP is comparable to BioMarin’s Voxzogo (vosoritide), … of infringing on BioMarin’s long-acting CNP patent portfolio, which … result in royalties to BioMarin.” The William Blair analyst …

… everyday needs become very difficult. BioMarin estimates the incidence of CLN2 … brain (cerebrospinal fluid) using BioMarin's patented technology. Brineura, the first … European Commission. Founded in 1997, BioMarin is a global biotechnology company …

… cerebrospinal fluid) using BioMarin's patented technology. BRINEURA, … future events or otherwise. BioMarin®, BioMarin RareConnections® and BRINEURA® …                       Andrew Villani BioMarin Pharmaceutical Inc.  BioMarin Pharmaceutical Inc. (415) 455 …

… GlobalData’s company profile on BioMarin Pharmaceutical, Human telomerase RT … key innovation area identified from patents. BioMarin Pharmaceutical's grant … Patent and Trademark Office (USPTO). Credit: BioMarin Pharmaceutical Inc A recently granted patent …

… article highlighted the undervaluation of BioMarin Pharmaceutical (NASDAQ:BMRN), and the … to decline due to the patent expiration, its sales amounted to … be sufficient for regulatory approval. BioMarin is planning to present the …

… oncology’s hottest space. BioMarin appeases an activist Alexander … the new CEO of BioMarin Pharmaceutical, had an unenviable … that attract activist pressure, BioMarin actually makes money, and … GlaxoSmithKline pulls back inhaler patents after FTC warning letter …